CROI 2017 Program and Information

Program and Agenda

Oral Abstract O-4: NEWHIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE Room 6 AB 10:00 AM - 12:00 PM Oral Abstract Moderators Sally Hodder, West Virginia Clinical and Translational Science Inst, Morgantown, WV, USA Yazdan Yazdanpanah, Inserm, IAME, Paris, France 38 DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORSWITH 10:00 LONG-ACTING POTENTIAL Winston C. Tse , John O. Link, Andrew Mulato, Anita Niedziela-Majka, William Rowe, John R. Somoza, Armando G. Villasenor, Stephen R. Yant, Jennifer R. Zhang, Jim Zheng Gilead Scis, Inc, Foster City, CA, USA 39 HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL 10:15 OF NANOPARTICLE ARV FORMULATIONS Andrew Owen 1 , Steve Rannard 1 , Akil Jackson 2 , Laura Dickinson 1 , Marco Giardiello 1 , Marco Siccardi 1 , Paul Domanico 3 , Melynda Watkins 3 , Yao Cheng 4 , Marta Boffito 5 1 Univ of Liverpool, Liverpool, UK, 2 Chelsea and Westminster Hosp, London, UK, 3 Clinton Hlth Access Initiative, Boston, MA, USA, 4 Med Patent Pool, Geneva, Switzerland, 5 Chelsea and Westminster NHS Fndn Trust, London, UK 40 CLINICAL PHARMACOLOGY OF THE HIV INTEGRASE STRAND 10:30 TRANSFER INHIBITOR BICTEGRAVIR Heather Zhang, Joseph M. Custodio , Xuelian Wei, Hui Wang, Amanda Vu, John Ling, Hal Martin, Erin Quirk, Brian P. Kearney Gilead Sci, Foster City, CA, USA 41 RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIRWITH 10:45 FTC/TAF FOR INITIAL HIV THERAPY Paul E. Sax 1 , Edwin DeJesus 2 , Gordon Crofoot 3 , Douglas Ward 4 , Paul Benson 5 , Xuelian Wei 6 , Kirsten L. White 6 , Hal Martin 6 , Andrew Cheng 6 , Erin Quirk 6 1 Brigham and Women’s Hosp, Boston, MA, USA, 2 Orlando Immunol Cntr, Orlando, FL, USA, 3 The Crofoot Rsr Cntr, Houston, TX, USA, 4 Dupont Circle Physicians Group, Washington, DC, USA, 5 Be Well Med Cntr, Berkley, MI, USA, 6 Gilead Scis, Inc, Foster City, CA, USA José L. Blanco 1 , Celia Oldenbuettel 2 , Réjean Thomas 3 , Josep Mallolas 1 , Eva Wolf 4 , Bluma Brenner 5 , Christoph D. Spinner 6 , Mark A. Wainberg 5 , Esteban Martinez 1 , for the Redo Group 1 Hosp Clinic Barcelona, Barcelona, Spain, 2 MVZ Karlsplatz, HIV Rsr and Clinical Care Cntr, München, Germany, 3 Clinique Médicale l'Actuel, Montreal, QC, Canada, 4 MUC Rsr, Munich, Germany, 5 McGill Univ, Montreal, Quebec, Canada, 6 Univ Hosp Klinikum Rechts der Isar, Munich, Germany 43 PREVALENCE AND IMPACT OF PRETREATMENT DRUG 11:15 RESISTANCE IN THE ANRS 12249 TASP TRIAL Anne Derache 1 , Collins C. Iwuji 2 , Siva Danaviah 1 , Anne-Geneviève Marcelin 3 , Vincent Calvez 3 , Tulio de Oliveira 4 , François Dabis 5 , Deenan Pillay 1 , for the ANRS 12249 Treatment as Prevention 1 Africa Hlth Rsr Inst, Mtubatuba, South Africa, 2 Univ Coll London, London, UK, 3 Pitie-Salpetriere Hosp, Paris, France, 4 Univ of KwaZulu-Natal, Durban, South Africa, 5 Univ de Bordeaux, Bordeaux, France 42 PATHWAYS OF RESISTANCE IN SUBJECTS FAILING 11:00 DOLUTEGRAVIRMONOTHERAPY

Oral Sessions • Tuesday

CROI 2017 37